Pfizer (PFE) News Today

Pfizer Inc. (PFE) sees mixed investor reactions today as its flagship blood thinner gains new patient‐direct initiatives and trial updates bolster the pipeline, while some profit‐taking and recent pullbacks weigh on sentiment.

• Positive Sentiment: Pfizer and Bristol Myers Squibb announced a direct-to-patient program for Eliquis, improving access for uninsured and underinsured patients starting September 8, 2025. Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program
• Positive Sentiment: Bristol-Myers Squibb and Pfizer will sell Eliquis directly to U.S. patients at a 40% discount, cutting monthly cash costs and bypassing middlemen. Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
• Positive Sentiment: Early data from a Phase 1A/B trial of PF-07799544 for advanced solid tumors showed encouraging safety and efficacy, strengthening Pfizer’s oncology pipeline. Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors
• Positive Sentiment: Results from a Phase 4 rimegepant study indicate strong migraine prevention efficacy, supporting growth in Pfizer’s neurology portfolio. Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention?
• Neutral Sentiment: Interim insights from Pfizer’s hemophilia study were released, offering a look at treatment patterns but without major surprises. Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes
• Neutral Sentiment: Updated data on the BeneFIX study were published, providing usage insights without altering the safety or efficacy outlook. Pfizer’s BeneFIX Study Update: Key Insights for Investors
• Neutral Sentiment: Post-marketing surveillance from the INLYTA® study in Taiwan was completed, supporting regional safety monitoring rather than driving significant new uptake. Pfizer’s INLYTA® Study in Taiwan: Key Insights for Investors
• Negative Sentiment: Ritholtz Wealth CEO Josh Brown disclosed he is selling Pfizer shares, citing valuation concerns after recent moves. Trade Tracker: Josh Brown Sells Pfizer
• Negative Sentiment: PFE’s recent 3.7% pullback has extended its one-year decline, raising speculation that institutional investors may adjust their holdings. Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures
• Negative Sentiment: A Reddit user reported selling Pfizer at a 13% loss, reflecting some retail investor caution around the stock. I Sold Pfizer at a 13% Loss – Here’s Why I’m Choosing Stability Over Risk